EP1474528A4 - Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer - Google Patents

Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer

Info

Publication number
EP1474528A4
EP1474528A4 EP01983958A EP01983958A EP1474528A4 EP 1474528 A4 EP1474528 A4 EP 1474528A4 EP 01983958 A EP01983958 A EP 01983958A EP 01983958 A EP01983958 A EP 01983958A EP 1474528 A4 EP1474528 A4 EP 1474528A4
Authority
EP
European Patent Office
Prior art keywords
methods
prostate cancer
modulators
diagnosis
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01983958A
Other languages
German (de)
French (fr)
Other versions
EP1474528A2 (en
Inventor
Kurt C Gish
David H Mack
Keith E Wilson
Daniel Afar
Peter Hevezi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Garvan Institute of Medical Research
Cedars Sinai Medical Center
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/847,046 external-priority patent/US20020068036A1/en
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Priority to EP07075380A priority Critical patent/EP1847620A3/en
Publication of EP1474528A2 publication Critical patent/EP1474528A2/en
Publication of EP1474528A4 publication Critical patent/EP1474528A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP01983958A 2000-10-13 2001-10-12 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer Withdrawn EP1474528A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07075380A EP1847620A3 (en) 2000-10-13 2001-10-12 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US687576 1984-12-28
US733288 1985-05-10
US68757600A 2000-10-13 2000-10-13
US73374200A 2000-12-08 2000-12-08
US73328800A 2000-12-08 2000-12-08
US733742 2000-12-08
US26395701P 2001-01-24 2001-01-24
US263957P 2001-01-24
US27688801P 2001-03-16 2001-03-16
US27679101P 2001-03-16 2001-03-16
US276888P 2001-03-16
US276791P 2001-03-16
US28192201P 2001-04-06 2001-04-06
US281922P 2001-04-06
US28621401P 2001-04-24 2001-04-24
US286214P 2001-04-24
US847046 2001-04-30
US09/847,046 US20020068036A1 (en) 2000-10-13 2001-04-30 Novel methods of diagnosis of prostate cancer and/or breast cancer, compositions, and methods of screening for prostate cancer and /or breast cancer modulators
US28858901P 2001-05-04 2001-05-04
US288589P 2001-05-04
PCT/US2001/032045 WO2002030268A2 (en) 2000-10-13 2001-10-12 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP07075380A Division EP1847620A3 (en) 2000-10-13 2001-10-12 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer

Publications (2)

Publication Number Publication Date
EP1474528A2 EP1474528A2 (en) 2004-11-10
EP1474528A4 true EP1474528A4 (en) 2006-06-14

Family

ID=27581207

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01983958A Withdrawn EP1474528A4 (en) 2000-10-13 2001-10-12 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer

Country Status (6)

Country Link
EP (1) EP1474528A4 (en)
JP (1) JP2005506033A (en)
AU (1) AU2002215345A1 (en)
CA (1) CA2425569A1 (en)
MX (1) MXPA03003151A (en)
WO (1) WO2002030268A2 (en)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2286304C (en) 1997-04-10 2007-08-07 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
ATE437947T1 (en) 1998-06-01 2009-08-15 Agensys Inc SERPENT TRANS MEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCER AND THEIR USES
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
EP1222266B1 (en) 1999-09-29 2006-03-29 Diagnocure Inc. Pca3 messenger rna in benign and malignant prostate tissues
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
US20020187524A1 (en) * 2000-12-15 2002-12-12 Millennium Pharmaceuticals, Inc. 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, and 67084 alt, human proteins and methods of use thereof
ATE396266T1 (en) 2000-07-28 2008-06-15 Ulrich Wissenbach TRP8 CANCER MARKER
US20030092009A1 (en) 2000-11-16 2003-05-15 Kaia Palm Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
AU2002246708A1 (en) 2000-12-15 2002-08-12 Agensys, Inc. Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US7081516B2 (en) 2002-08-26 2006-07-25 Case Western Reserve University Methods for categorizing patients
US7118912B2 (en) * 2002-08-26 2006-10-10 Case Western Reserve University Methods and compositions for categorizing patients
CA2439702A1 (en) * 2001-03-05 2002-09-19 Aventis Pharma S.A. Nucleic acids of the human abcc11 gene, vectors containing such nucleic acids and uses thereof
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2000482A1 (en) * 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2005508157A (en) 2001-08-31 2005-03-31 アジェンシス，インコーポレイテッド 205P1B5 nucleic acid and corresponding protein useful in cancer treatment and detection
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2003022995A2 (en) 2001-09-06 2003-03-20 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
JP2005519137A (en) * 2001-09-17 2005-06-30 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Methods for using 46828 human acyl-CoA synthetase
US20030100034A1 (en) * 2001-10-16 2003-05-29 Millennium Pharmaceuticals, Inc. 9136, a human aldehyde dehydrogenase family member and uses therefor
WO2003054512A2 (en) * 2001-12-20 2003-07-03 Tularik Inc. Identification of an amplified gene and target for drug intervention
US20030235533A1 (en) * 2002-02-19 2003-12-25 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
WO2005067629A2 (en) * 2004-01-06 2005-07-28 Avalon Pharmaceuticals Cancer-linked genes as targets for chemotherapy
US20040162236A1 (en) * 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
DE60328979D1 (en) * 2002-05-10 2009-10-08 Jackson H M Found Military Med ANDROGEN-REGULATED PMEPA1 GENE AND METHOD FOR ITS USE TO INHIBIT CANCER GROWTH
DE10234901A1 (en) * 2002-07-26 2004-02-12 Metagen Pharmaceuticals Gmbh New nucleic acids encoding Mrp4, useful in the diagnosis of prostatic, bladder and ovarian tumors, also in screening for specific binding agents, and potential therapeutic agents
US7408048B2 (en) 2002-08-09 2008-08-05 Melbourne Health Mammalian grainyhead transcription factors
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
CA2496781A1 (en) * 2002-08-26 2004-03-04 Case Western Reserve University Methods for treating patients and identifying therapeutics
WO2004053495A1 (en) * 2002-12-09 2004-06-24 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with phosphodiesterase 9a1 (pde9a1)
CA2513780C (en) 2003-02-07 2014-12-30 Diagnocure Inc. Method to detect prostate cancer from a urine sample
JP2004357702A (en) * 2003-05-09 2004-12-24 Research Association For Biotechnology New protein and dna encoding the same
US7473531B1 (en) 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
US20070253954A1 (en) * 2004-02-27 2007-11-01 Oncotherapy Science, Inc. Epha4 As Therapeutic Target Of Prc And Pdaca
NZ550816A (en) 2004-04-22 2009-12-24 Agensys Inc Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2005106488A2 (en) * 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled beta-2 adrenoceptor (adrb2)
BRPI0510883B8 (en) 2004-06-01 2021-05-25 Genentech Inc drug-antibody conjugate compound, pharmaceutical composition, method of manufacturing a drug-antibody conjugate compound, and uses of a formulation, a drug-antibody conjugate and a chemotherapeutic agent, and a combination
US20090004193A1 (en) * 2004-07-23 2009-01-01 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated With Vasoactive Intestinal Peptide Receptor 1 (Vpac1)
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2006060533A2 (en) 2004-12-01 2006-06-08 Genentech, Inc. Conjugates of 1, 8-bis-naphthalimides with an antibody
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
WO2006074914A2 (en) * 2005-01-13 2006-07-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Human rna helicase and therapeutic uses thereof
DK2325305T3 (en) 2005-02-25 2014-03-03 Oncotherapy Science Inc Peptide vaccines for cancers that express TTK-, URLC10- or KOC1 polypeptide
RU2639543C9 (en) 2006-10-27 2018-06-14 Дженентек, Инк. Antibodies and immunoconjugates and their applications
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2171090B1 (en) * 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
WO2009032292A1 (en) * 2007-09-06 2009-03-12 Case Western Reserve University Methods for diagnosing and treating cancers
JP5589274B2 (en) * 2007-10-25 2014-09-17 東レ株式会社 Immune inducer
US9249409B2 (en) * 2007-10-25 2016-02-02 Toray Industries, Inc. Method for detection of cancer
AU2014240339B2 (en) * 2007-10-25 2017-07-13 Toray Industries, Inc. Method for detection of cancer
WO2010009124A2 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
TWI543767B (en) 2008-08-19 2016-08-01 腫瘤療法 科學股份有限公司 Hig2 and urlc10 epitope peptide and vaccines containing the same
IN2012DN03025A (en) 2009-09-09 2015-07-31 Ct Se Llc
PE20130342A1 (en) 2010-04-15 2013-04-20 Spirogen Sarl PIRROLOBENZODIACEPINES AND CONJUGATES OF THE SAME
CN102958941A (en) * 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 Compositions and methods for the diagnosis and treatment of tumor
RU2626537C2 (en) 2010-06-08 2017-07-28 Дженентек, Инк. Antibodies with cysteine substituitions and their conjugates produced by gene engineering
ES2544608T3 (en) 2010-11-17 2015-09-02 Genentech, Inc. Antibody and alaninyl-maitansinol conjugates
WO2012155019A1 (en) 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
EP2750713B1 (en) 2011-10-14 2015-09-16 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AU2013328628B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
ES2660029T3 (en) 2012-10-12 2018-03-20 Medimmune Limited Antibody-pyrrolobenzodiazepine conjugates
PL2906253T3 (en) 2012-10-12 2019-02-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
MX364329B (en) 2012-10-12 2019-04-23 Medimmune Ltd Pyrrolobenzodiazepine-antibody conjugates.
KR101819404B1 (en) 2012-10-12 2018-02-28 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
CN105102068B (en) 2012-10-12 2018-06-01 Adc疗法责任有限公司 Pyrrolobenzodiazepines Zhuo-antibody conjugates
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
CA2894959C (en) 2012-12-21 2022-01-11 Spirogen Sarl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
CN110452242A (en) 2012-12-21 2019-11-15 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
BR112015023070B1 (en) 2013-03-13 2022-06-07 Genentech, Inc. Pyrrolobenzodiazepine conjugates and compounds, pharmaceutical composition comprising the same, as well as their uses for the treatment of a proliferative disease
KR102066318B1 (en) 2013-03-13 2020-01-14 메디뮨 리미티드 Pyrrolobenzodiazepines and conjugates thereof
JP6444902B2 (en) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugates
CA2904441A1 (en) * 2013-03-15 2014-09-18 Metamark Genetics, Inc. Compositions and methods for cancer prognosis
BR112016002829A2 (en) 2013-08-12 2017-09-19 Genentech Inc COMPOUND AND PROCESS FOR PREPARING ANTIBODY-DRUG CONJUGATE COMPOUND, PHARMACEUTICAL COMPOSITION, CANCER TREATMENT METHOD, CANCER TREATMENT KIT, DRUG LINKER INTERMEDIATE, CBI DIMER DRUG MOUNT AND COMPOUND
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
MX371092B (en) 2013-12-16 2020-01-16 Genentech Inc Peptidomimetic compounds and antibody-drug conjugates thereof.
EA201691023A1 (en) 2013-12-16 2016-10-31 Дженентек, Инк. PEPTIDOMIMETIC CONNECTIONS AND THEIR CONJUGATES ANTIBODIES WITH MEDICINE
KR20160092024A (en) 2013-12-16 2016-08-03 제넨테크, 인크. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US20150252425A1 (en) * 2014-03-05 2015-09-10 Caldera Health Ltd. Gene expression profiling for the diagnosis of prostate cancer
CN106687141A (en) 2014-09-10 2017-05-17 麦迪穆有限责任公司 Pyrrolobenzodiazepines and conjugates thereof
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
KR20170052600A (en) 2014-09-12 2017-05-12 제넨테크, 인크. Cysteine engineered antibodies and conjugates
AU2015317653A1 (en) 2014-09-17 2017-04-06 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
CN107148285B (en) 2014-11-25 2022-01-04 Adc治疗股份有限公司 Pyrrolobenzodiazepine-antibody conjugates
CN107206101B (en) 2014-12-03 2021-06-25 基因泰克公司 Quaternary ammonium compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201510684D0 (en) * 2015-06-17 2015-08-05 Almac Diagnostics Ltd Gene signatures predictive of metastatic disease
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (en) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド Multiple whole antibody and antibody complex drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
CN109313200B (en) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 Bioanalytical methods for characterizing site-specific antibody-drug conjugates
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CN110139674B (en) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 Method for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
PL3544636T3 (en) 2017-02-08 2021-12-06 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
JP7247101B2 (en) 2017-04-03 2023-03-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Antibody that binds to STEAP-1
RS63502B1 (en) 2017-04-18 2022-09-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
NZ761175A (en) 2017-08-18 2024-07-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
TW201920192A (en) 2017-09-20 2019-06-01 韓商Ｐｈ製藥公司 THAILANSTATIN analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2020010305A1 (en) * 2018-07-05 2020-01-09 The Board Of Regents Of The University Of Oklahoma Gene signatures for cancer characterization and methods of use
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028498A1 (en) * 1994-04-15 1995-10-26 The Trustees Of Columbia University In The City Of New York Method for molecular staging of prostate cancer
US5858673A (en) * 1996-06-24 1999-01-12 Charlotte-Mecklenburg Hospital Authority Method for detecting prostate cells
WO1999037811A1 (en) * 1998-01-21 1999-07-29 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
WO1999042622A1 (en) * 1998-02-23 1999-08-26 Dana-Farber Cancer Institute, Inc. Method for identifying mismatch repair glycosylase reactive sites, compound and uses thereof_____________________________________
WO1999064594A2 (en) * 1998-06-11 1999-12-16 Chiron Corporation Genes and gene expression products that are differentially regulated in prostate cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055208A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028498A1 (en) * 1994-04-15 1995-10-26 The Trustees Of Columbia University In The City Of New York Method for molecular staging of prostate cancer
US5858673A (en) * 1996-06-24 1999-01-12 Charlotte-Mecklenburg Hospital Authority Method for detecting prostate cells
WO1999037811A1 (en) * 1998-01-21 1999-07-29 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
WO1999042622A1 (en) * 1998-02-23 1999-08-26 Dana-Farber Cancer Institute, Inc. Method for identifying mismatch repair glycosylase reactive sites, compound and uses thereof_____________________________________
WO1999064594A2 (en) * 1998-06-11 1999-12-16 Chiron Corporation Genes and gene expression products that are differentially regulated in prostate cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CARLISLE A J ET AL: "Development of a prostate cDNA microarray and statistical gene expression analysis package", MOLECULAR CARCINOGENESIS, ALAN LISS, NEW YORK, NY,, US, vol. 28, no. 1, May 2000 (2000-05-01), pages 12 - 22, XP002225396, ISSN: 0899-1987 *
DATABASE EMBL [online] 21 November 1996 (1996-11-21), "zk91c02.s1 Soares_pregnant_uterus_NbHPU Homo sapiens cDNA clone IMAGE:490178 3', mRNA sequence.", XP002339482, retrieved from EBI accession no. EM_HUM:HSAA21266 Database accession no. HSAA21266 *
DATABASE NETAFFX [online] Affymetrix; 12 April 2006 (2006-04-12), XP002376990, retrieved from HTTPS://WWW.AFFYMETRIX.COM/ANALYSIS/NETAFFX/FULLRECORD.AFFX?PK=HUGENEFL%3AU41060_AT *
ELEK J ET AL: "MICROARRAY-BASED EXPRESSION PROFILING IN PROSTATE TUMORS", IN VIVO - INTERNATIONAL JOURNAL OF IN VIVO RESEARCH, GB, vol. 14, no. 1, January 2000 (2000-01-01), pages 173 - 182, XP001027452, ISSN: 0258-851X *
GREEN C ET AL: "Human Breast Cancer, estrogen regulated LIV-1 protein (LIV-1) mRNA, partial cds", ENTREZ NUCLEOTIDE, 6 April 1996 (1996-04-06), XP002175106 *
LADEANA HILLIER ET AL: "Generation and analysis of 280,000 human expressed sequence tags", PCR METHODS AND APPLICATIONS, COLD SPRING HARBOR, NY, US, vol. 6, no. 9, September 1996 (1996-09-01), pages 807 - 828, XP002140684, ISSN: 1054-9803 *
XU JIANGCHUN ET AL: "Identification of differentially expressed genes in human prostate cancer using subtraction and microarray", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 6, 15 March 2000 (2000-03-15), pages 1677 - 1682, XP002198982, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
JP2005506033A (en) 2005-03-03
CA2425569A1 (en) 2002-04-18
EP1474528A2 (en) 2004-11-10
WO2002030268A2 (en) 2002-04-18
WO2002030268A3 (en) 2004-08-26
AU2002215345A1 (en) 2002-04-22
MXPA03003151A (en) 2003-08-19

Similar Documents

Publication Publication Date Title
EP1474528A4 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
EP1434881A4 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
AU2002245317A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
AU3983201A (en) Compositions and methods for the early diagnosis of ovarian cancer
AU3491001A (en) Compositions and methods for the early diagnosis of ovarian cancer
HUP0203968A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1515982A4 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001231199A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
AU2002347428A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2002309583A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002252144A1 (en) Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002249871A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
EP1317669A4 (en) Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
AU3752700A (en) Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU3755300A (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
AU2002246519A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
EP1349485A4 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001290518A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2002357734A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030428

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060517

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GARVAN INSTITUTE OF MEDICAL RESEARCH

17Q First examination report despatched

Effective date: 20061103

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CEDARS-SINAI MEDICAL CENTER

Owner name: GARVAN INSTITUTE OF MEDICAL RESEARCH

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ANGUS, DAVID B.

Inventor name: HEVEZI, PETER

Inventor name: AFAR, DANIEL

Inventor name: WILSON, KEITH, E.

Inventor name: MACK, DAVID, H.

Inventor name: GISH, KURT, C.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070914